CoChat

Immunological analysis of the murine anti‐CD3‐induced cytokine release syndrome model and therapeutic efficacy of anti‐cytokine antibodies

Open access
Nouveau, Lise, Buatois, Vanessa, Cons, Laura, Chatel, Laurence, Pontini, Guillemette, Pleche, Nicolas, Ferlin, Walter G. · 2021 · European Journal of Immunology

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

The aberrant release of inflammatory mediators often referred to as a cytokine storm or cytokine release syndrome (CRS), is a common and sometimes fatal complication in acute infectious diseases including Ebola, dengue, COVID-19, and influenza. Fatal CRS occurrences have also plagued the development of highly promising cancer therapies based on T-cell engagers and chimeric antigen receptor (CAR) T cells. CRS is intimately linked with dysregulated and excessive cytokine release, including IFN-γ, TNF-α, IL 1, IL-6, and IL-10, resulting in a systemic inflammatory response leading to multiple organ failure. Here, we show that mice intravenously administered the agonistic hamster anti-mouse CD3ε monoclonal antibody 145-2C11 develop clinical and laboratory manifestations seen in patients afflicted with CRS, including body weight loss, hepatosplenomegaly, thrombocytopenia, increased vascular permeability, lung inflammation, and hypercytokinemia. Blood cytokine levels and gene expression analysis from lung, liver, and spleen demonstrated a hierarchy of inflammatory cytokine production and infiltrating immune cells with differentiating organ-dependent kinetics. IL-2, IFN-γ, TNF-α, and IL-6 up-regulation preceded clinical signs of CRS. The co-treatment of mice with a neutralizing anti-cytokine antibody cocktail transiently improved early clinical and laboratory features of CRS. We discuss the predictive use of this model in the context of new anti-cytokine strategies to treat human CRS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/eji.202149181

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 26

Metadata

Authors
Nouveau, L., Buatois, V., Cons, L., Chatel, L., Pontini, G., Pleche, N., & Ferlin, W. G.
Affiliations
  • Light Chain Bioscience (Switzerland) (CH)
  • Light Chain Bioscience‐Novimmune S.A. Geneva Switzerland
Corresponding author
Ferlin, Walter G.
Venue
European Journal of Immunology
Publisher
Wiley
Published
2021-05-19
Volume
51
Issue
8
Pages
2074-2085
ISSN
  • 0014-2980 (ISSN-L)
  • 1521-4141
OpenAlex
W3157468375
Cited by
25
References
60
Citations by year
2026: 8 · 2025: 1 · 2024: 5 · 2023: 6 · 2022: 4 · 2021: 1
FWCI
2.61
Type
journal article
Language
en
Open access
Locations
  • European Journal of Immunology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
  • Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords
cytokine release syndrome, CD3ε, interleukin-6, interferon-gamma, TNF-α, interleukin-2, cytokine storm, T-cell engagers, CAR T-cell therapy, systemic inflammatory response, lung inflammation, hepatosplenomegaly, thrombocytopenia, vascular permeability, cytokine gene expression
MeSH terms
Cytokine Release Syndrome, Animals, Antibodies, Antibodies, Monoclonal, Disease Models, Animal, Drug Therapy, Combination, Lymphocyte Activation, Phenotype, Severity of Illness Index, T-Lymphocytes, Cytokines, Treatment Outcome, CD3 Complex, Inflammation Mediators, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.